This is a working overview of glucagon receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-07 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
=== Iran === The celebration of Persian New Year, or Nowruz, dating back over 3,000 years, marks the advent of spring, and tulips are used as a decorative feature during the festivities. The 12th century Persian tragic romance, Khosrow and Shirin, similar to the tale of Romeo and Juliet, tells of tulips sprouting where the blood of the young prince Farhad spilt after he killed himself upon hearing the (deliberately false) story that his true love had died. The tulip was a topic for Persian poets from the thirteenth century. The poem Gulistan by Musharrifu'd-din Saadi, described a visionary garden paradise with "The murmur of a cool stream / bird song, ripe fruit in plenty / bright multicoloured tulips and fragrant roses...". Tulips have featured in the poems of Simin Behbahani. The tulip is the national symbol for martyrdom in Iran (and Shi'ite Islam generally), and has been used on postage stamps and coins. It was common as a symbol used in the 1979 Islamic Revolution, and a red tulip adorns the flag redesigned in 1980. The sword in the centre, with four crescent-shaped petals around it, create the word "Allah" as well as symbolising the five pillars of Islam. The tomb of Ayatollah Ruhollah Khomeini is decorated with 72 stained glass tulips, representing 72 martyrs who died at the Battle of Karbala in 680 CE. It was also used as a symbol on billboards celebrating casualties of the 1980–1988 war with Iraq.
1883-1897 Charles Roy - Professor of Pathology & Head of Department 1897-1898 Alfredo Kanthack - Professor of Pathology & Head of Department 1899-1922 German Sims Woodhead - Professor of Pathology & Head of Department 1922-1961 Henry Roy Dean - Professor of Pathology & Head of Department 1962-1975 Ronald Greaves - Professor of Pathology & Head of Department 1975-1987 Peter Wildy - Professor of Pathology & Head of Department 1987-1998 Malcolm Ferguson-Smith - Professor of Pathology & Head of Department 1998-2011 Andrew Wyllie - Professor of Pathology & Head of Department 2011-2022 Geoffrey Smith - Professor of Pathology & Head of Department 2022- Heike Laman - Head of Department (re-elected in 2025) 2023- Adrian Liston - Professor of Pathology
==== Solid phase extraction ==== Solid phase extraction also can be used to isolate YTXs from the sample medium. This technique separates the components of a mixture by using their different chemical and physical properties. This method is robust and extremely useful when small sample volumes are being analysed. It is advantageous over solvent extraction, as it concentrates (can give sample enrichment up to the power of 10) and can purify the sample by the removal of salts and nonpolar substances which can interfere with the final analysis. This technique is also beneficial because it gives good levels of YTX recovery — ranging from 40 to 50%.
Sources: en.wikipedia.org
=== Diet === The coastal taipan's diet consists predominantly of rats, mice, and bandicoots, with various species of birds taken opportunistically. In 2010, a dead coastal taipan was found to have ingested a cane toad. Whether the snake had been poisoned by the toad and died, or had resisted the poison and been killed by a vehicle (as it was found on a road with neck trauma) was unknown. When hunting, it appears to actively scan for prey using its well-developed eyesight, and is often seen traveling with its head raised slightly above ground level. Once prey is detected, the snake "freezes" before hurling itself forward and issuing several quick bites. The prey is released and allowed to stagger away. This strategy minimises the snake's chance of being harmed in retaliation, particularly by rats, which can inflict lethal damage with their long incisors and claws. The coastal taipan closely resembles the African black mamba (Dendroaspis polylepis) in body shape, venom toxicity, and hunting behaviour—both employing a "snap and release" strategy. This convergence is thought due to their adaptation to hunting mammals; the large size is needed to eat large prey, and lethal venom is to immobilise prey quickly before they can damage the predator.
Legio XIV Gemina Martia Victrix (Twin martial and victorious): 57 BC – 48 BC: Julius Caesar, destroyed and reconstituted in 53 BC. Reconstituted by Octavian after 41 BC. Legio XV Apollinaris (Apollo's) 41 BC – 40 BC, Octavian, raised to end the occupation of Sicily by Sextus Pompeius. Legio XVI Gallica (Gallic) 41 BC – 40 BC, Octavian, disbanded after Batavian revolt in AD 70. Legio XVII raised by Octavian in 41 BC, destroyed in Teutoburg forest in AD 9 with XVIII and XIX legions. Legio XVIII raised by Octavian in 41 BC, destroyed in Teutoburg forest in AD 9 with XVII and XIX legions Legio XIX raised by Octavian in 41 BC, destroyed in Teutoburg forest in AD 9 with XVII and XVIII legions Legio XX Valeria Victrix (Victorious Valeria) raised by Octavian in 31 BC. Legio XX Siciliana: 36 BC – 6 BC, Octavian probably for his campaign against Sextus Pompey. Legio XXI Rapax (Predator) raised by Octavian in 31 BC Legio XXV: 49 BC – 42 BC, Julius Caesar Legio XXVI: 49 BC – 30 BC, Julius Caesar legio XXVII: 49 BC – 30 BC, Julius Caesar Legio XXVIII: 47 BC – 31 BC, Julius Caesar Legio XXIX: 49 BC – 30 BC, Julius Caesar Legio XXX Classica (Naval): 48 BC – 41 BC, Julius Caesar
Observations in vitro and of tumours extracted from those five patients suggest that DCA might act against cancer cells by depolarising abnormal mitochondria found in glioblastoma cancer cells – allowing the mitochondria to induce apoptosis (cell death) of the malignant cells. In vitro work with DCA on neuroblastomas (which have fewer recognised mitochondrial abnormalities) showed activity against malignant, undifferentiated cells. A 2016 case report discussed and reviewed the application of DCA in central nervous system malignancies. A 2018 study found that DCA could trigger a metabolic switch from glycolysis (the Warburg effect) to mitochondrial OXPHOS and increase reactive oxygen stress affecting tumor cells. These effects were not observed in non-tumor cells. Current research has focused mainly on combining DCA with other cancer drugs to form prodrug complexes which can release both agents in a more targeted manner.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.